Postmenopausal osteoporosis is caused due to estrogen deficiency, which is the most common type of osteoporosis. Estrogen deficiency results in an increase in bone turnover owing to effects on all types of bone cells. The imbalance in bone formation and resorption has effects on trabecular bone (loss of connectivity) and cortical bone (cortical thinning and porosity). Osteoporosis is diagnosed using bone density measurements of the lumbar spine and proximal femur. Preventive strategies to improve bone health include diet, exercise, and abstaining from smoking. Several drugs are licensed to reduce fracture risk by slowing down bone resorption (such as bisphosphonates and Denosumab) or by stimulating bone formation (such as teriparatide). Improved understanding of the cellular basis for osteoporosis has resulted in new drugs targeted to key pathways, which are under development.
Global postmenopausal osteoporosis market is estimated to be valued at US$ 4,547.8 million in 2022 and is expected to exhibit a CAGR of 4.4% during the forecast period (2022-2030).
Analysts’ Views on Global Postmenopausal Osteoporosis Market:
The global postmenopausal osteoporosis market is expected to grow in near future owing to the robust pipeline of drugs indicated for the treatment of postmenopausal osteoporosis, which may increase the number of product approvals and product launches over the forecast period. For instance, on October 13, 2022, Radius Health, Inc., a commercial biopharmaceutical company, announced that data from the Phase 3 Abaloparatide for the treatment of men with osteoporosis clinical trial (NCT03512262) evaluating abaloparatide compared to placebo had been published. TYMLOS (abaloparatide) is a human parathyroid hormone-related peptide analog already indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The successful ATOM study has been published in The Journal of Bone and Mineral Research (JBMR). TYMLOS is an excellent molecule, and it can be used as a treatment option for patients with postmenopausal osteoporosis.
Figure 1. Global Postmenopausal Osteoporosis Market Share (%), by Drug Class, 2022
Global Postmenopausal Osteoporosis Market- Drivers
Increasing research and development activities among research institutes and market players
The development of treatment indicated for postmenopausal osteoporosis through increased research and development activities among research institutes and market players is expected to drive market growth over the forecast period. For instance, on June 8, 2022, Bone Health Technologies (BHT), a company focused on therapies for bone diseases such as osteoporosis, announced that it will be conducting a 1-year long study of a novel, non-drug intervention to treat osteopenia in postmenopausal women, in partnership with the San Francisco Veterans Affairs Health Care System (SFVAHCS), the University of California, San Francisco (UCSF), and the Northern California Institute for Research and Education (NCIRE). BHT is looking to enroll 50 patients with diverse racial and ethnic backgrounds who are not currently taking any osteoporosis drugs and have dual-energy X-ray absorptiometry (DXA) scan bone density T-scores between -1.0 and -2.4. This study can help to understand treatment options and suitable drug options for the treatment of postmenopausal osteoporosis in the near future.
Postmenopausal Osteoporosis Market Report Coverage
|Base Year:||2021||Market Size in 2022:||US$ 4,547.8 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.4%||2030 Value Projection:||US$ 6,442.6 Mn|
Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
|Restraints & Challenges:||
Increasing product approval by regulatory authorities
Increasing product approvals by regulatory authorities is expected to drive ther growth of global postmenopausal osteoporosis market over the forecast period. For instance, On December 19, 2022, Radius Health, Inc., a biopharmaceutical company announced that the European Commission has granted marketing authorization for abaloparatide under the tradename of ELADYNOS to treat osteoporosis in postmenopausal women at increased risk of fracture. Abaloparatide has been approved in the U.S. since April 2017 under the tradename of TYMLOS. Abaloparatide is a PTHrP (1-34) analog that stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity leading to a reduction of new fractures. Abaloparatide is supplied as a single-patient multi-use prefilled pen designed to administer 80 micrograms per dose over a 30-day period.
Figure 2. Global Postmenopausal Osteoporosis Market Share (%), by Region, 2022
Global Postmenopausal Osteoporosis Market - Regional Analysis
Among all regions, North America is expected to dominate the global market over the forecast period owing to the guidance by multidisciplinary organization. For instance, on September 7, 2021, The North American Menopause Society (NAMS), a nonprofit, multidisciplinary organization, released a new position statement outlining the organization’s guidance for the management of osteoporosis in postmenopausal women. The statements recommend the use of T-score at the hip as an appropriate target for guiding therapy choices, as current evidence suggests bone mineral density measured on-treatment correlates with the patient’s risk of fracture. The statement also outlines differing treatment approaches for women at very high risk of fracture, which calls for beginning treatment with a bone-building agent followed by an anti-remodeling agent, such as bisphosphonates and Denosumab.
The Europe region is expected to hold second largest postion in all region over the forecast period. For instance, on May 25, 2022, The U.K. National Institute for Health and Care Excellence (NICE) recommended the sclerostin inhibitor romosozumab as a treatment option for postmenopausal patients in England and Wales who have had a major osteoporotic fracture in previous 24 months. Romosozumab represents the first new class of drug available for the treatment of osteoporosis in nearly 10 years and is the first osteoporosis drug to both reduce bone resorption and stimulate bone formation. Its developers, Amgen and UCB, estimate that more than 20,000 people in England and Wales could be eligible for the treatment.
Global Postmenopausal Osteoporosis Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting the production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with the transportation of drugs and vaccines from one place to another.
the COVID-19 pandemic had a negative impact owing to the COVID-19 lockdown negatively impacted on adherence to Denosumab therapy. The COVID-19 pandemic has negatively impacted on clinical outcomes of osteoporotic patients with ongoing Denosumab treatment, revealing a higher prevalence of non-adherent patients and a higher number of new non-traumatic fractures (including rebound fractures) during the lockdown period in comparison to the pre-COVID-19 period, regardless of the modality of medical evaluation. Hence, tele-medicine seems to be an alternative strategy to standard face-to-face visits in guaranteeing the continuity of follow-up in osteoporotic patients and short-term compliance with Denosumab.
Global Postmenopausal Osteoporosis Market Segmentation:
The global postmenopausal osteoporosis market report is segmented into Drug Class, Route of Administration, and Distribution Channel.
Based on Drug Class, the market is segmented into Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors, Anabolic Class, Calcium Metabolism Modifiers, and Others (Calcitonin, Denosumab, among Others). Out of which, the Bisphosphonates segment is expected to dominate the global postmenopausal osteoporosis market during the forecast period and an increase in the usage of Bisphosphonates for the treatment of Postmenopausal Osteoporosis.
Based on Route of Administration, the market is segmented into Oral, Intravenous Route, and Subcutaneous. Out of which, the Oral segment is expected to dominate the market over the forecast period and increase in the use of oral suspension for treatments of various diseases such as Postmenopausal Osteoporosis
Based on Distribution Channel, the postmenopausal osteoporosis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to an increase in the number of hospital pharmacies.
Global Postmenopausal Osteoporosis Market Cross Sectional Analysis:
In drug class segment, others segment is dominant in the Europe region due to the increasing number of product approvals by regulatory authorities such as European Medicines Agency (EMA). For instance, on November 14, 2022, Stelis Biopharma Limited (Stelis or Company), the biologics arm of Strides Pharma Science Limited, announced that its product division Biolexis had a major success with its first biosimilar product KaulivTM, which received a positive recommendation from European Medicines Agency (EMA) for granting of market authorization. KaulivTM is a recombinant human teriparatide injection intended for the treatment of osteoporosis. KaulivTM is a biosimilar to Forsteo (innovator product), indicated for both men and postmenopausal women with osteoporosis who are at high risk for having broken bones or fractures.
Global Postmenopausal Osteoporosis Market: Key Developments
On June 13, 2022, Innovent Biologics, Inc., a world-class biopharmaceutical company and PT Etana Biotechnologies Indonesia, an Indonesia-based biotechnology company, jointly announced that the Indonesian Food and Drugs Authority (Badan Pengawas Obat dan Makanan) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody drug, for five indications including metastatic colorectal cancer (mCRC), locally recurrent or metastatic triple-negative breast cancer (mTNBC), advanced, metastatic, or recurrent non-small cell lung cancer(NSCLC), epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC), and cervical cancer(CC).
Global Postmenopausal Osteoporosis Market: Restraint
Side effects from postmenopausal osteoporosis treatments
The major factors that hinder the growth of the global postmenopausal osteoporosis market include side effects from postmenopausal osteoporosis treatments. For instance, on January 5, 2021, an article published in JAMA, a peer review journal, stated that bisphosphonates for postmenopausal osteoporosis frequently result in very uncommon adverse effects, like a rare thigh bone fracture and a lack of blood supply to the jawbone (osteonecrosis of the jaw) (atypical femoral fracture). The most frequent cause of jaw osteonecrosis is invasive dental work like tooth extraction. Before having this kind of treatment, women using bisphosphonates should speak with their doctor to determine whether to cease the drug. More than five years of bisphosphonate use may raise the chance of an atypical femoral fracture.
Global Postmenopausal Osteoporosis Market- Key Players
Major players operating in the global postmenopausal osteoporosis market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
Frequently Asked Questions